The increasing cases of several health problems such as sepsis to boost the antithrombin market growth
Antithrombin Market, By Application (Therapeutics, Research, and
Diagnostics), By Source (Human, Goat Milk, and Others), By Dosage Form
(Lyophilized and Liquid), and By Geography - Size, Share, Outlook, and
Opportunity Analysis, 2022-2028
The global antithrombin market
is estimated to be valued at reach US$ 811.3
million by in 2027 and is expected to exhibit a CAGR
of 4.1 % over the forecast period, as highlighted in a new report published by
Coherent Market Insights.
Market Overview:
Antithrombin is a small glycoprotein that deactivates various enzymes of the coagulation method. It is an amino-acid protein generated by the liver.Antithrombin is a protein in the plasma that stops the formation of irregular blood clots. It aids the body keep a hearty balance in bleeding and coagulation.
Competitive Landscape:
Major players involved in the global antithrombin market are Scripps Laboratories Inc., Green Cross Corp., Grifols, Shire Plc., rEVO Biologics Inc., Lee Bisolutions, CSL Limited, GTC Biotherapeutics, Inc.’s, Kedrion S.p.A, and BDI Pharma.
Market Key Drivers:
The increasing cases of several health problems such as
sepsis, disseminated intravascular coagulation, congenital antithrombin
deficiency, and ECMO is expected to augment the growth of global antithrombin
market. For instance, as per WHO, it
affects around 47 and 50 million people annually, around 11 million
fatalities, one death per every 2.8 seconds.
The rising prevalence of open heart surgeries is
anticipated to fuel the growth of global antithrombin market. As per the facts
and figures collected from a source around 500,000 million have undergone the
open heart surgery.
Covid-19 Impact Analysis:
COVID‐19 is a highly prothrombotic disorder, often
necessitating anticoagulation for obstruction or cure of thrombosis and to
allow organ support. The published cases of thrombosis in patients with
COVID‐19 differs significantly based on anticoagulant routine, seriousness of
disorder and other risk factors such as central lines. Hence the person distressed
from disease has a high chance to be agonized from the COVID-19.
Key Takeaways:
The
global antithrombin market is anticipated to exhibit a CAGR of 4.43 % during
the forecast period due to rising cases of Venous thromboembolism or VTE. For
instance, as per the worldthrombosis.org around 10 million people globally
suffer from VTE.
Among regions, North America, Europe, and Asia Pacific are expected to
witness robust growth in the global antithrombin market due to rising prevalence
of VTE, increasing product approvals and frequent product launches by the key
players and diseases such as Antithrombin deficiency. For instance, as per ASH 900,000 people in the US suffer from blood
clots annually, and they are responsible for around 100,000 fatalities annually.
Comments
Post a Comment